Although experimental evidence indicates that PPM1D mutations confer resistance to cancer therapy in hematopoietic cells [25, 48, 53, 54, 55], large studies have demonstrated that PPM1D‐mutated CH is not clearly associated with an increased risk of hematologic malignancies in both noncancer [23] and nonhematologic cancer [24] cohorts. Here, PPM1D is linked to hematologic disorder.